GreenLight Biosciences Holdings, (GRNA): Price and Financial Metrics
GRNA Price/Volume Stats
| Current price | $0.30 | 52-week high | $5.90 |
| Prev. close | $0.30 | 52-week low | $0.18 |
| Day low | $0.30 | Volume | 143,100 |
| Day high | $0.30 | Avg. volume | 486,986 |
| 50-day MA | $0.27 | Dividend yield | N/A |
| 200-day MA | $0.85 | Market Cap | 45.43M |
GRNA Stock Price Chart Interactive Chart >
GreenLight Biosciences Holdings, (GRNA) Company Bio
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and a range of crops. The company was founded in 2008 and is based in Medford, Massachusetts.
Latest GRNA News From Around the Web
Below are the latest news stories about GREENLIGHT BIOSCIENCES HOLDINGS PBC that investors may wish to consider to help them evaluate GRNA as an investment opportunity.
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private TransactionGreenLight Biosciences GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction |
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressImage: GreenLight Biosciences Image: GreenLight Biosciences BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023. “GreenLight is sharply focused on its mission, leveraging scientific expertise, global partnerships, and the power of our platform to |
GreenLight Biosciences Releases Inaugural Sustainability ReportGreenLight greenhouse GreenLight is sharing its business strategy and how it can impact food security, biodiversity, health, and climate in its 2022 Sustainability Report. BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report. The report contains the company's |
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall LineGreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line Image: GreenLight Biosciences BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today, confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, |
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial ResultsGreenLight's RTP greenhouse facility in North Carolina GreenLight's RTP greenhouse facility in North Carolina Two agriculture solutions now under regulatory review, pending EPA approval: Calantha™, a solution to protect potatoes, and a separate solution to protect honeybees from Varroa miteUpdated clinical strategy to accelerate development of its next-generation Covid vaccine candidate; decision to advance universal pan-sarbecovirus vaccine candidatePresented promising preclinical immune respon |
GRNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -3.38% |
| 3-year | -96.92% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -88.10% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...